[go: up one dir, main page]

DK2827883T3 - Tfpi-inhibitorer og fremgangsmåder til anvendelse - Google Patents

Tfpi-inhibitorer og fremgangsmåder til anvendelse Download PDF

Info

Publication number
DK2827883T3
DK2827883T3 DK13703505.1T DK13703505T DK2827883T3 DK 2827883 T3 DK2827883 T3 DK 2827883T3 DK 13703505 T DK13703505 T DK 13703505T DK 2827883 T3 DK2827883 T3 DK 2827883T3
Authority
DK
Denmark
Prior art keywords
methods
tfpi inhibitors
tfpi
inhibitors
Prior art date
Application number
DK13703505.1T
Other languages
English (en)
Inventor
Frank Osterkamp
Michael Dockal
Rudolf Hartmann
Friedrich Scheiflinger
Thomas Polakowski
Ulrich Reineke
Original Assignee
Baxalta GmbH
Baxalta Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxalta GmbH, Baxalta Inc filed Critical Baxalta GmbH
Application granted granted Critical
Publication of DK2827883T3 publication Critical patent/DK2827883T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/811—Serine protease (E.C. 3.4.21) inhibitors
    • G01N2333/8114—Kunitz type inhibitors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK13703505.1T 2012-03-21 2013-01-31 Tfpi-inhibitorer og fremgangsmåder til anvendelse DK2827883T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261613865P 2012-03-21 2012-03-21
PCT/US2013/024167 WO2013141965A1 (en) 2012-03-21 2013-01-31 Tfpi inhibitors and methods of use

Publications (1)

Publication Number Publication Date
DK2827883T3 true DK2827883T3 (da) 2019-07-29

Family

ID=47682077

Family Applications (1)

Application Number Title Priority Date Filing Date
DK13703505.1T DK2827883T3 (da) 2012-03-21 2013-01-31 Tfpi-inhibitorer og fremgangsmåder til anvendelse

Country Status (16)

Country Link
US (3) US8962563B2 (da)
EP (1) EP2827883B1 (da)
JP (2) JP2015514070A (da)
KR (2) KR20140143191A (da)
CN (3) CN109111505A (da)
AU (2) AU2013235741C1 (da)
BR (1) BR112014022435B1 (da)
CA (1) CA2867363C (da)
DK (1) DK2827883T3 (da)
ES (1) ES2733958T3 (da)
HR (1) HRP20191160T1 (da)
HU (1) HUE046572T2 (da)
LT (1) LT2827883T (da)
NZ (3) NZ724133A (da)
SI (1) SI2827883T1 (da)
WO (1) WO2013141965A1 (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9580758B2 (en) 2013-11-12 2017-02-28 Luc Montagnier System and method for the detection and treatment of infection by a microbial agent associated with HIV infection
WO2015131061A1 (en) 2014-02-28 2015-09-03 Baxalta Incorporated Peptides and methods of use
EP3194447B1 (en) * 2014-09-17 2021-12-01 Novo Nordisk A/S Antibodies capable of binding two epitopes on tissue factor pathway inhibitor (1-161)
EP3455636B1 (en) * 2016-05-13 2023-08-23 The Scripps Research Institute Compositions and methods for anti-thrombotic and hemostatic therapies
CN118930608A (zh) * 2019-07-08 2024-11-12 3B制药有限公司 包含成纤维细胞活化蛋白配体的化合物及其用途
SI3997103T1 (sl) 2019-07-08 2025-04-30 3B Pharmaceuticals Gmbh Spojine, ki obsegajo ligand proteina za aktiviranje fibroblastov in uporaba le teh
IL295797A (en) * 2020-02-22 2022-10-01 Japan Chem Res Human transferrin receptor binding peptide
EP4326303A4 (en) * 2021-04-18 2025-03-05 Rambam Med-Tech Ltd. PROCOAGULATING PEPTIDES AND THEIR USE
JP2025509154A (ja) 2022-03-08 2025-04-11 エクアシールド メディカル リミテッド ロボット医薬品調製システムにおける流体移送ステーション
US20240216504A1 (en) * 2022-12-30 2024-07-04 Dong Kyu Jin Method for preventing or treating of hemathrosis

Family Cites Families (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
JPS5733175A (en) 1980-07-31 1982-02-23 Mitsubishi Electric Corp Transmitter for signal of elevator
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
JPS607193A (ja) 1983-06-25 1985-01-14 古河電気工業株式会社 回路基板用半田付炉
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4966852A (en) 1987-07-23 1990-10-30 Monsanto Company DNA clone of human tissue factor inhibitor
IL87171A (en) 1987-11-23 1995-08-31 Monsanto Co cDNA of human tissue factor inhibitor
US5663143A (en) 1988-09-02 1997-09-02 Dyax Corp. Engineered human-derived kunitz domains that inhibit human neutrophil elastase
US5219994A (en) 1988-11-08 1993-06-15 W. Alton Jones Cell Science Center, Inc. Inhibitor of tissue factor activity
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
US5622988A (en) 1990-06-15 1997-04-22 Novo Nordisk A/S Use of a low molecular weight metabolite from fungus for reducing prolonged coagulation time
DK146190D0 (da) 1990-06-15 1990-06-15 Novo Nordisk As Hidtil ukendte forbindelser
US5849703A (en) 1990-08-27 1998-12-15 G. D. Searle & Co. Pre-formed anticoagulant heparin/TFPI complexes
DK261490D0 (da) 1990-10-31 1990-10-31 Novo Nordisk As New pharmaceutical compound
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
JPH04252954A (ja) 1991-01-29 1992-09-08 Asahi Chem Ind Co Ltd タンパクの測定方法、試薬及びキット
US5833982A (en) 1991-02-28 1998-11-10 Zymogenetics, Inc. Modified factor VII
US5997864A (en) 1995-06-07 1999-12-07 Novo Nordisk A/S Modified factor VII
JPH067193A (ja) 1991-11-29 1994-01-18 Teijin Ltd モノクローナル抗体
EP0539975A1 (en) 1991-10-31 1993-05-05 Teijin Limited Method for immunological assay of free lipoprotein-associated coagulation inhibitor (LACI) and kit therefor
IL104324A0 (en) 1992-01-07 1993-05-13 Novo Nordisk As Variant of human kunitz-type protease inhibitor
IL104326A0 (en) 1992-01-07 1993-05-13 Novo Nordisk As Variant of human kunitz-type protease inhibitor
IL104327A0 (en) 1992-01-07 1993-05-13 Novo Nordisk As Variant of human kunitz-type protease inhibitor
IL104325A (en) 1992-01-07 2000-10-31 Novo Nordisk As Variants of human kunitz-type protease inhibitor domain II of tissue factor pathway inhibitor (TFPI) pharmaceutical compositions containing them a DNA construct encoding them their expression vectors a cell containing said DNA constructs and methods for the production of all the above
IL104314A0 (en) 1992-01-07 1993-05-13 Novo Nordisk As Human kunitz-type protease inhibitor and variants thereof,their production and pharmaceutical compositions containing them
WO1994002172A1 (en) 1992-07-24 1994-02-03 Oklahoma Medical Research Foundation Blockade of protein c activation reduces microvascular surgical blood loss
JPH06153985A (ja) 1992-11-16 1994-06-03 Teijin Ltd モノクローナル抗体
US5439686A (en) 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
PT693924E (pt) 1993-02-22 2004-09-30 American Biosciences Processos para administracao (in vivo) de substancias biologicas e composicoes utilizadas nestes processos
WO1995007986A1 (en) 1993-09-14 1995-03-23 Genentech, Inc. Pharmaceutical compositions containing ecotin and homologs thereof
US5455338A (en) 1993-11-05 1995-10-03 Zymogenetics, Inc. DNA encoding novel human kunitz-type inhibitors and methods relating thereto
DE69533544T2 (de) 1994-01-11 2006-02-23 Dyax Corp., Cambridge Inhibitoren des humanplasmins, die sich von den kunitz domänen ableiten
US5902582A (en) 1995-09-05 1999-05-11 Chiron Corporation Use of TFPI inhibitor for treatment of cancer
JP3681206B2 (ja) 1995-12-26 2005-08-10 株式会社三菱化学ヤトロン 抗ファクターＸａ・ティシュファクターパスウェイインヒビター複合体モノクローナル抗体及びその使用
EP1005551A2 (en) 1997-01-31 2000-06-07 Human Genome Sciences, Inc. Tissue factor pathway inhibitor-3
US20050032690A1 (en) 1997-09-10 2005-02-10 Rojkjaer Lisa Payne Factor VII polypeptides for preventing formation of inhibitors in subjects with haemophilia
JP2002503701A (ja) 1998-02-18 2002-02-05 ハーバー−ユーシーエルエイ リサーチ アンド エデュケーション インスティテュート 抗菌性ペプチドおよび誘導したメタペプチド
JP2000128803A (ja) 1998-10-19 2000-05-09 Shionogi & Co Ltd ティッシュ・ファクター・パスウェイ・インヒビター−２抗体
KR20020042622A (ko) 1999-07-23 2002-06-05 코애귤레이션 다이어그노스틱스, 인크. 전혈내 응고 인자 활성을 측정하는 방법
US6180607B1 (en) 1999-08-05 2001-01-30 Christopher Davies Protein having proteinase inhibitor activity
US6458387B1 (en) 1999-10-18 2002-10-01 Epic Therapeutics, Inc. Sustained release microspheres
EP1232178A2 (en) 1999-11-16 2002-08-21 The General Hospital Corporation Compositions and methods for regulating tumor-associated antigen expression
US6821775B1 (en) 2000-02-11 2004-11-23 Genvec, Inc. Viral vector encoding pigment epithelium-derived factor
US7015194B2 (en) 2000-05-10 2006-03-21 Novo Nordisk A/S Pharmaceutical composition comprising factor VIIa and anti-TFPI
EP1282438B1 (en) 2000-05-10 2005-08-03 Novo Nordisk Health Care AG Use of pharmaceutical composition comprising a factor viia and a factor xiii
AU2001263215A1 (en) 2000-05-16 2001-11-26 Genentech Inc. Method for treating cartilage disorders
WO2002033089A2 (en) 2000-10-05 2002-04-25 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Ixodes scapularis tissue factor pathway inhibitor
DE60138641D1 (de) 2000-10-27 2009-06-18 Baxter Healthcare Sa Herstellung von mikrokügelchen
US20030040480A1 (en) 2001-07-20 2003-02-27 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and factor XI polypeptides
JP2004534855A (ja) 2001-07-20 2004-11-18 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 第ｖｉｉ因子ポリペプチドおよび第ｘｉ因子ポリペプチドを含んでなる医薬組成物
WO2003015750A1 (en) 2001-08-16 2003-02-27 Baxter International, Inc. Propellant-based microparticle formulations
US20080026068A1 (en) 2001-08-16 2008-01-31 Baxter Healthcare S.A. Pulmonary delivery of spherical insulin microparticles
US20030211075A1 (en) 2001-09-27 2003-11-13 Thorpe Philip E. Combined compositions for tumor vasculature coagulation and treatment
CN1176943C (zh) * 2001-10-08 2004-11-24 复旦大学 新型重组人组织因子途径抑制物活性肽及其制备方法
US7291587B2 (en) 2001-11-09 2007-11-06 Novo Nordisk Healthcare A/G Pharmaceutical composition comprising factor VII polypeptides and TAFI polypeptides
EP1446145A1 (en) 2001-11-09 2004-08-18 Novo Nordisk Health Care AG Pharmaceutical composition comprising factor vii polypeptides and tafi polypeptides
US20050214836A1 (en) 2002-08-30 2005-09-29 Oncotherapy Science, Inc. Method of diagnosing ovarian endometriosis
AU2003265866A1 (en) 2002-09-03 2004-03-29 Vit Lauermann Targeted release
EP1403638A1 (en) 2002-09-25 2004-03-31 Mondobiotech SA Molecular methods for diagnosing interstitial lung diseases
WO2004063337A2 (en) 2003-01-07 2004-07-29 Dyax Corporation Kunitz domain library
EP1620567A1 (en) 2003-04-15 2006-02-01 Hans-Jürgen Thiesen Method for diagnosing rheumatoid arthritis or osteoarthritis
US20070092452A1 (en) 2003-07-18 2007-04-26 Julia Rashba-Step Methods for fabrication, uses, compositions of inhalable spherical particles
JP2007531701A (ja) 2003-07-18 2007-11-08 バクスター・インターナショナル・インコーポレイテッド 制御された相分離により調製される小球状粒子の作製方法、使用および組成物
US20050142205A1 (en) 2003-07-18 2005-06-30 Julia Rashba-Step Methods for encapsulating small spherical particles prepared by controlled phase separation
US20050048127A1 (en) 2003-07-22 2005-03-03 Larry Brown Small spherical particles of low molecular weight organic molecules and methods of preparation and use thereof
EP1664291B1 (en) 2003-09-09 2012-02-29 Novo Nordisk Health Care AG Coagulation factor vii polypeptides
ES2381110T3 (es) 2003-09-09 2012-05-23 Novo Nordisk Health Care Ag Polipéptidos de factor VII de coagulación
EP1668371B1 (en) 2003-09-24 2012-05-09 Oncotherapy Science, Inc. Method of diagnosing ovarian endometriosis using tfpi-2 protein
PL1667743T3 (pl) 2003-09-29 2008-06-30 Hemoteq Ag Biokompatybilne, biostabilne pokrycie powierzchni medycznych
US20090232866A1 (en) 2003-10-07 2009-09-17 Mariann Pavone-Gyongyosi Oligopeptides as coating material for medical products
US20050181978A1 (en) 2003-11-20 2005-08-18 Rasmus Rojkjaer Therapeutic use of factor XI
EP1692313A2 (en) 2003-11-20 2006-08-23 Sanofi Pasteur Inc. Methods for purifying pertussis toxin and peptides useful therefor
RU2006115783A (ru) 2003-11-20 2007-12-27 Ново Нордиск Хелс Кеа Аг (Ch) Терапевтическое применение фактора xi
US20050147689A1 (en) 2003-12-30 2005-07-07 Egilmez Nejat K. Method for inhibiting the growth of gastrointestinal tract tumors
JP2007523705A (ja) 2004-02-28 2007-08-23 ヘモテック アーゲー 医療用品表面の生体適合性コーティング、方法、および使用
EP1750758A1 (en) 2004-05-11 2007-02-14 Novo Nordisk Health Care AG Use of factor viia for the treatment of burn traumas
CA2566075A1 (en) 2004-05-12 2005-12-01 Baxter Healthcare S.A. Microspheres comprising protein and showing injectability at high concentrations of said agent
US8728525B2 (en) 2004-05-12 2014-05-20 Baxter International Inc. Protein microspheres retaining pharmacokinetic and pharmacodynamic properties
WO2005115442A1 (en) 2004-05-25 2005-12-08 Novo Nordisk Health Care Ag Use of coagulation factor xiii for treatment of post surgical bleedings
RU2347574C2 (ru) 2004-05-27 2009-02-27 Эвиджен, Инк. Способы лечения коагулопатий с использованием сульфатированных полисахаридов
EP1761630A2 (en) 2004-06-21 2007-03-14 Novo Nordisk Health Care AG Glycosylation-disrupted factor vii variants
WO2006008267A2 (en) 2004-07-16 2006-01-26 Novo Nordisk Health Care Ag Methods for optimizing forming viiia-based hemostatic treatment
US20060040896A1 (en) 2004-08-18 2006-02-23 Paringenix, Inc. Method and medicament for anticoagulation using a sulfated polysaccharide with enhanced anti-inflammatory activity
JP4252954B2 (ja) 2004-12-02 2009-04-08 インターナショナル・ビジネス・マシーンズ・コーポレーション 情報処理装置、情報処理装置のパワーマネージメント方法、およびそのためのプログラム
EP1855712A2 (en) 2005-02-28 2007-11-21 Novo Nordisk Health Care AG Fxiii variants with improved properties
US7682808B2 (en) 2005-03-04 2010-03-23 The Board Of Trustees Of The University Of Illinois Coagulation and fibrinolytic cascades modulator
JP2008539259A (ja) 2005-04-27 2008-11-13 バクスター・インターナショナル・インコーポレイテッド 表面を修飾した微粒子およびその形成方法および使用
KR20080008364A (ko) 2005-05-05 2008-01-23 헤모텍 아게 관 스텐트의 전면 코팅
WO2006128497A1 (en) 2005-06-01 2006-12-07 Novo Nordisk A/S Pharmaceutical formulation of factor xi
US20080161425A1 (en) 2005-07-29 2008-07-03 Universiteit Van Maastricht Regulation of Tissue Factor Activity by Protein S and Tissue Factor Pathway Inhibitor
DE102005039579B4 (de) 2005-08-19 2022-06-30 Magforce Ag Verfahren zur Einschleusung von therapeutischen Substanzen in Zellen
GB0525999D0 (en) 2005-12-21 2006-02-01 Ares Trading Sa Novel members of the kazal family of serine protease inhibitors
EP3150236B1 (de) 2006-02-09 2018-12-26 B. Braun Melsungen AG Faltenballonbeschichtungsverfahren
US20070192033A1 (en) 2006-02-16 2007-08-16 Microsoft Corporation Molecular interaction predictors
WO2007127834A2 (en) 2006-04-26 2007-11-08 Medtronic, Inc. Compositions and methods of preparation thereof
US20070281031A1 (en) 2006-06-01 2007-12-06 Guohan Yang Microparticles and methods for production thereof
EP1892303A1 (en) 2006-08-22 2008-02-27 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Methods for identifying therapeutical targets in tumors and for determining and targeting angiogenesis and hemostasis related to adenocarcinomas of the lung
EP1895436A1 (en) 2006-08-31 2008-03-05 Silicos NV Method for evolving molecules and computer program for implementing the same
EP1913962A1 (en) 2006-10-22 2008-04-23 Ophir Perelson Expandable medical device for the treatment and prevention of cardiovascular diseases
KR101486931B1 (ko) 2007-02-23 2015-01-27 박스터 인터내쇼날 인코포레이티드 해조류 추출물로부터 푸코이단을 정제하는 방법
EP1972687A1 (en) 2007-03-23 2008-09-24 GenOdyssee Polynucleotides and polypeptides of human factor VII gene, SNPs
US20100137211A1 (en) 2007-04-11 2010-06-03 Monahan Paul E Methods and compositions for intra-articular coagulation proteins
DK2915564T3 (da) 2007-09-28 2021-02-08 Alexion Pharma Inc Antidoter mod faktor XA-inhibitorer og fremgangsmåder til anvendelse deraf
US20100297257A1 (en) 2007-11-09 2010-11-25 National Institutes Of Health (Nih), U.S. Dept. Of Health And Human Services (Dhhs) Anticoagulant antagonist and hemophillia procoagulant
US20110027337A1 (en) 2007-12-21 2011-02-03 Ifxa A/S Protease inhibitor
FR2934052B1 (fr) 2008-07-17 2011-11-25 Stago Diagnostica Dosage de l'activite du facteur tissulaire circulant
UA112050C2 (uk) 2008-08-04 2016-07-25 БАЄР ХЕЛСКЕР ЛЛСі Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
CN102112157B (zh) 2008-08-06 2013-05-29 诺沃-诺迪斯克保健股份有限公司 具有延长的体内效能的缀合蛋白
KR100994996B1 (ko) 2008-08-06 2010-11-18 한국과학기술연구원 페난트렌 노출 여부 확인용 바이오마커 및 이를 이용한확인 방법
SI2379096T1 (sl) 2008-12-19 2020-03-31 Baxalta GmbH Zaviralci TFPI in postopki uporabe
CA2793465C (en) * 2010-03-19 2022-06-14 Baxter International Inc. Tfpi inhibitors and methods of use
EP2569000B1 (en) 2010-05-13 2017-09-27 Indiana University Research and Technology Corporation Glucagon superfamily peptides exhibiting nuclear hormone receptor activity
PT2694544T (pt) * 2011-04-01 2019-04-02 Bayer Healthcare Llc Anticorpos monoclonais contra inibidor da via do fator tecidual (tfpi)
JP6153985B2 (ja) 2015-10-16 2017-06-28 株式会社スクウェア・エニックス ビデオゲーム処理プログラム、ビデオゲーム処理システム及びビデオゲーム処理方法

Also Published As

Publication number Publication date
CN104302306B (zh) 2019-03-22
LT2827883T (lt) 2019-08-12
CN109111505A (zh) 2019-01-01
BR112014022435A2 (pt) 2017-07-11
US10800816B2 (en) 2020-10-13
CN104302306A (zh) 2015-01-21
AU2017221855B2 (en) 2019-08-22
AU2013235741B2 (en) 2017-06-15
EP2827883A1 (en) 2015-01-28
NZ724133A (en) 2020-07-31
AU2013235741A1 (en) 2014-09-18
HUE046572T2 (hu) 2020-03-30
CA2867363C (en) 2023-02-28
BR112014022435B1 (pt) 2023-02-14
NZ749998A (en) 2023-06-30
US9873720B2 (en) 2018-01-23
CA2867363A1 (en) 2013-09-26
US8962563B2 (en) 2015-02-24
EP2827883B1 (en) 2019-05-08
US20130252896A1 (en) 2013-09-26
US20170174727A1 (en) 2017-06-22
WO2013141965A1 (en) 2013-09-26
SI2827883T1 (sl) 2019-08-30
ES2733958T3 (es) 2019-12-03
JP2015514070A (ja) 2015-05-18
US20180155399A1 (en) 2018-06-07
CN109134614A (zh) 2019-01-04
HK1206282A1 (en) 2016-01-08
AU2013235741C1 (en) 2017-12-21
KR20140143191A (ko) 2014-12-15
KR102263685B1 (ko) 2021-06-11
JP2019108360A (ja) 2019-07-04
JP7303640B2 (ja) 2023-07-05
NZ629130A (en) 2016-10-28
AU2017221855A1 (en) 2017-09-21
KR20200014448A (ko) 2020-02-10
HRP20191160T1 (hr) 2019-10-04

Similar Documents

Publication Publication Date Title
DK2815066T3 (da) Selektivt korroderbart borehulsartikel og fremgangsmåde til anvendelse
DK2900657T3 (da) Cykliske etherpyrazol-4-yl-heterocyclyl-carboxamidforbindelser og fremgangsmåder til anvendelse
DK2929031T5 (da) Pcsk9-irna-sammensætninger og fremgangsmåder til anvendelse deraf
DK2844292T3 (da) ST2L-antagonister og fremgangsmåder til anvendelse
HRP20182037T1 (hr) Inhibitori prmt5 i njihova uporaba
DK2970205T3 (da) JAK2- og ALK2-inhibitorer og fremgangsmåder til anvendelse deraf
DK2683731T3 (da) C4-monomethyl-triterpenoidderivater og fremgangsmåder til anvendelse deraf
DK2914627T3 (da) Anti-cd40-antistoffer og fremgangsmåder til anvendelse
DK3087095T3 (da) FcRn-antagonist og fremgangsmåder til anvendelse
IL244488A0 (en) Inhibitors of erk and methods of use
DK2675827T3 (da) Hidtil ukendte modulatorer og fremgangsmåder til anvendelse
DK2857401T3 (da) Hidtil ukendt -lactamaseinhibitor og fremgangsmåde til at fremstille samme
DK2882496T3 (da) Behandling og diagnosticering af melanom
SG11201504022RA (en) Glutamase inhibitors and method of use
SI2909204T1 (sl) Inhibitorji GSK3 in postopki njihove uporabe
DK3550836T3 (da) Fremgangsmåde og anordning til afkodning
DK2961831T3 (da) Sammensætninger og fremgangsmåder til immunterapi
DK2872153T3 (da) Accellulære pro-tolerogene sammensætninger og fremgangsmåde til fremstilling heraf
DK2914575T3 (da) Plasminogen-aktivator-1-inhibitorer og fremgangsmåder til anvendelse deraf
DK3049056T4 (da) Topisk antisvampesammensætning og fremgangsmåder til behandling
DK2827883T3 (da) Tfpi-inhibitorer og fremgangsmåder til anvendelse
DK2892912T3 (da) C17-alkandiyl og alkenediylderivater af oleanolsyre og fremgangsmåder til anvendelse deraf
DK2838900T3 (da) Forbindelser og fremgangsmåder til antiviral behandling
DK3082902T3 (da) Kropsbåret injektor og anvendelsesmetode
DK3086807T3 (da) Antistoffer og fremgangsmåder til anvendelse